N
Google TrendANNA BONDAR (200+) — October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:anna bondar200+natanael cano100+green card500+power outage near me10000+india2000+sony playstation1000+loki100+hubert hurkacz200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Clinical Trial Failure Is" (30 stories)

Top Headline Story

AI companies run virtual drug trials, aim to improve success of human studies
Lead StoryReuterstech
3d ago

AI companies run virtual drug trials, aim to improve success of human studies

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRzNEYVFhV3haR0RGX2RWa0FjcmxRQlFTLTYwRFc1SlowRDNpUWlwdUd6NVFJVnZha25pZV9jZDlvX21ERllna0tsT01zRE9wUjZSbzg4Zk9XZmwwUEZ3dXkwZ01TWFlKU21lVV80RkdfU0d0d2NIVjV2LTk3NExQUFpzX3JqNENQY1FnOE1sR0xQOW1SWGdRdGVmenlieWlVbnlFY3BKczVnTlBuczUzQTVHZkx0Tkx1bEh5ZVZVbGs?oc=5" target="_blank">AI companies run virtual drug trials, aim to improve success of human studies</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+21m ago

anna bondar

October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market

Filter stories
100+21m ago

natanael cano

Padres de Natanael Cano rompen el silencio tras retiro del cantante: "Es por el bien de nuestro hijo"

Filter stories
500+31m ago

green card

Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows

Filter stories
10000+31m ago

power outage near me

LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east

Filter stories

Search Results for "Clinical Trial Failure Is"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
ArriVent’s stock plummets on Phase III NSCLC trial failure
Clinical Trials Arenatech

ArriVent’s stock plummets on Phase III NSCLC trial failure

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQcjk5bTBXd0YzTTR0WDBGcTFHekFteU1jbXRveC1fb2EzM0xLY2NLLTNIZUdWbWJ4TV9DbVJObnZBUUYyR185b1RJZTJ4VzdBTGI3VnNabGRjanNWS0JPdFlXc0pfLVZHMWJraUNnTW5qY05NeUhoOHlSTnRrZm9qMDNldDQ2bGVLenVRY0daenY0RTFSNFp6Sms0S3U5SzlW?oc=5" target="_blank">ArriVent’s stock plummets on Phase III NSCLC trial failure</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
STATtech

Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOdElDMHVUa0gzVThrS3lHYmNQZTB5V2x1RFJRR0tCbnR6R3BHVHNZOFcyT0dOcGlnb3hUQ0FWWS10bkNsLVlxQlNtQWp2N3NwZ0ZjSU1iUE9HWXlYeHJjVGh3VE5jcER6RnJ3a2lLMHBsT2tyYjB1R3BLeUxmUnJRRXpsbw?oc=5" target="_blank">Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
AI companies see success in predicting drug failures after building virtual human trials
The Independenttech

AI companies see success in predicting drug failures after building virtual human trials

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNMkFtXzRhckg4MzJ1OHZIT0tBTFQzbHNVUWZoYUFHM3hVMk8tV20yeXA4YkJ0VmJNVUFSb2JxWXl5cGxIZ3A5SWJXNWt2ZW94X21ITHJaTVMycUdqOGdOdU43c3RHcHRDRElmUFJQVHRTdWo0M0N0OEtkeXA5bGVFdm1udm5UOXZVMVdtanVYdHotYkxUVVdtc2JSdw?oc=5" target="_blank">AI companies see success in predicting drug failures after building virtual human trials</a>  <font color="#6f6f6f">The Independent</font>

Read Full StoryMore like this
Jazz and PharmaMar Just Ran Out of Runway: Zepzelca’s Confirmatory Failure Is an Accelerated Approval System Under Stress
The Clinical Trial Vanguardtech

Jazz and PharmaMar Just Ran Out of Runway: Zepzelca’s Confirmatory Failure Is an Accelerated Approval System Under Stress

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxNX01EWU5UV1NyRmRidm9ldWdfWmp1ZlhVQXQ3YlJFa0F2djZ0X3dYal9McTB6WUNvVGdhSTlOSmZVQU1KbUtrQ0ZQTHVqeExYNC00SHpfbkQ4WTU3QTY0QWtQTGJTLWpqSlhXYnBwTHd1cGhKVXFlbzV0R1JLdkw2b3otLWNRSk5DSGNEMF9POGFyX2pnc3BFTS10OUYtUGc3Qkc1WDYzMm1kVmxyNWd6WGcxSzgwZkYwbU5udjM2MTJ5clBWV1NZLVZKSW9paFhtZUh5eDNRQWxXWG51cUg1czNqVkJTelowYmx6MTFWOE5Qd1NING1SMEQwUUxDY3k5NlZ4ajlB?oc=5" target="_blank">Jazz and PharmaMar Just Ran Out of Runway: Zepzelca’s Confirmatory Failure Is an Accelerated Approval System Under Stress</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
Cholesterol drug setback casts doubt over multibillion-dollar race
CNBCpolitics

Cholesterol drug setback casts doubt over multibillion-dollar race

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxONzY5UGlEQWY2S1VwcnpFeVZuMnNsb3k5NmI4SzBNUzM3Z0I5NnRTbmtkU01tMDktTjBvcTFPczgzcGFhRTdJekRHT1RLcXppbE90bFB4c0dsUm9VTHFnTkJPOGlYRHpXZkZiVHlxdWZYRDFzSWdoX2ozVVpCdTNoUVJQT1p1ZnIzQXNCZkZScUhtV3o3eEHSAZsBQVVfeXFMTjZKTzVJZ1JXaElEVmxyYjFkX3hfT2cyZ293cURFR2pIalJjRGEtejhHWF9yNUtPRXdlX3BnWTBkX04zMnEyX2hBTHNvSXdWNzdaVXRjWFVzdGx5TDZxdWJ2NGlMNzlhSF9IUXhEUWVvYVhuUnNTQlVsaWNqcWtCTmhXOEVCMElWeFZMbHEwdFVYd20xTmNXeHYtbzA?oc=5" target="_blank">Cholesterol drug setback casts doubt over multibillion-dollar race</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025
Applied Clinical Trialsgeneral

Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNM3duQ3lqTXM0WGFMMGxzNzRIQTZSdURNRjVRNkp3dDQ3QlhXbW1GdWxhTk1OWEQxTDFkTEg2NW12My1iRFFXQVVHVHdjSFpUSFl1Wkx6Sm1MY1p5S0wxMmFSNG81TjkzcUhtVHJ3R0xTNmhRbTZBYnVOSFJqQ1M5UE9JZzR4anFXNXFtakdVUE03czFwV0Y0UHBMVVI0VlA4T0E?oc=5" target="_blank">Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026
Business Wiretech

Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxNRFJwTVR5b0l4WTlIVjFyQ2NKZnJQU05qWlJQNGJrUWs3cHlPWVdmazZrUC1heUtCYnVEM0ZETTBwcFp0X09EdzVudjFVeUxZUVRyRkJNWnZXNWtRanRGeUZQbmstM3hxTC04SkUzWTdTU0xhZWVYOFN0TkhqdWpHamVtNFJGTW9neUZRRWNzeWhLWUVTUVpVODlxYi1FOFVhb0UyQUFTNm93eE11WFdDbmtIZ2poSTYxcnhLc2I2eFZqS1R4eVhWT3o4N2xnYjVENExIWk80aUphcWZ0NjlmUG5KdDBjQVYwYjVjN0xDYXk5TkVGNU5GY1k2cDRSX3JtSFM0X2ZaVHNKVVJMLUZrSmhiOVNOOWlZc0Nid3ktWG5SNVNrZzVOWFNtdHdGanUycldB?oc=5" target="_blank">Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Novartis RNA drug falls short in rare muscle disease study
BioPharma Divegeneral

Novartis RNA drug falls short in rare muscle disease study

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOVzVoNDk1RTlBVFFpSFJoQjJaZTUwUHhISjJEdC1OMi1pU3BzQ0xoSXFwNk5IRWRXVHFrRUtNQTByQUM1Qi0xUTBfdXA1aHZ4TEtQTXQwd0NqMEttT2lUck54WGFXZ3gwb2VFZTZOQ3NXeXk0YV9DQXRvVGg1ai1lLVMzM0NFa1kxZFlWREVRNTVUc1JHNEVZ?oc=5" target="_blank">Novartis RNA drug falls short in rare muscle disease study</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
The New York Timestech

A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNc3AwRDJkbTFVeWxMMmNoVHp6djJDMFNON0Q2anNNNTVtOGNWd1VXU2ZrQks2MlhRVHNmdGpnYXFzWWY1SVlpUVRTYml6a0VGb3NSdkxYeEF2YTJPRmg0UlBtckk0NzZoelJxYzBYLXdXSmtjdW5YOWxiT0tNX2hsMUZsM3NmeTh0UEVjcS13?oc=5" target="_blank">A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease</a>  <font color="#6f6f6f">The New York Times</font>

Read Full StoryMore like this
When a failed trial isn't a failed drug
Drug Discovery Newstech

When a failed trial isn't a failed drug

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxONnQ1eEY3NEg4aHFsRHBnMmt5eVpxQWYtLVdzTUp3V1lvSnJJZk1QNnRaRnRxdk5GME94c1pnc3ZuekNuSHhBNUMxaXlicVpFWEtPZU5tbHlwaEZVWkFHeGNiMzRxbFQtazRUMGwwRUpvS3pnaG5pWkJZZmFOODk5SWRmNEVwUQ?oc=5" target="_blank">When a failed trial isn't a failed drug</a>  <font color="#6f6f6f">Drug Discovery News</font>

Read Full StoryMore like this
Effectiveness of telemonitoring on clinical outcomes in patients with heart failure: a randomized clinical trial
Naturetech

Effectiveness of telemonitoring on clinical outcomes in patients with heart failure: a randomized clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5JODA4b213QUs3R1luN2pZRGczZGQxSkZ4V0x3TWRhZ2JpRlIyRXRCZWJTWnBFZXUzeS1nSUZWNDJrUy03MWx2Wk9rVU9wZ0UtUUhld1JVU3ItQUFENkNV?oc=5" target="_blank">Effectiveness of telemonitoring on clinical outcomes in patients with heart failure: a randomized clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Novartis halts ALS drug development after mid-stage trial failure
Reuterstech

Novartis halts ALS drug development after mid-stage trial failure

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOXzQ0aGlxRTVDWHZadUloUUk2bGhfMDAxdEkybkI3VnhQeVpjeUREX2dNSU9hOGZRb0M2TWhDV1lLSXhDem9KRnQwQ0dtYkgwTEJtSmRfNlA1WUhkZ3VOcFgzbXRXWmNBWHA2RU1NdXI1el9LV05vVUNIeXJvYV9URUpzUmQ2ZzZiUnlUbzZ6cGhIcklldC0xeHVNa3c2eThjLUJYaVZ0X2NMV3JBTmFXSmFLemY1Qng3aHlnUVhqX3VlNUY0bGhKQlAtR0dYODE5bUJB?oc=5" target="_blank">Novartis halts ALS drug development after mid-stage trial failure</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
AI-Driven Clinical Trial Recruitment and Design
Applied Clinical Trialstech

AI-Driven Clinical Trial Recruitment and Design

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPQzYwbDduY1R2aVRFNUEzZE52bjFMY0V1WnRHSVhqQ0hhbHNuUE94LWpVVHV0VDV0XzB4UGc0dENPbXlITW94TTdjRE5WM3lHbmVsRzRWRFJHdjFuR1Q3aTdqakNhUnlqX2l6LTc3eE5XeXdrR3hEdlBMVnA3b3pzQWdsWDN6d2lDV1B6SHZ0ZzhvMEppRTRJ?oc=5" target="_blank">AI-Driven Clinical Trial Recruitment and Design</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Heart failure drug from Tenax Therapeutics fails in pivotal study
STATtech

Heart failure drug from Tenax Therapeutics fails in pivotal study

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNc0RMMW9ud3NWMW1NTDB2OGlXd0cxbDgySVBjNWhqdENWdXB3TDVBZDZaelNpcWY4bktiZE5EWXg1RGFIV2NaZUUwX3FrcFEzOERBRFRlSUtxUFlSUGtxdWpIY05WaXluTUswT3VHTkdCX25uY0pYZGV0cG5HTEFSM1htSHc1d3V4MFZiamU3RlpzQlBoT2Z4aE9nMFNjUQ?oc=5" target="_blank">Heart failure drug from Tenax Therapeutics fails in pivotal study</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
CNBCmarkets

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPMDQyN2hzSzZrYVFOY3F1RUtzSENYRlUyZk5zaHBZVERYQVY1V0UwN2thZXNqQW5vdXctUFR4emVhVjdSaGt0WjdIMFMwZ1A3LXYzczFpWkJ5TDIxd0E4RGNfYzR1SndVU3lXcm9yUFhZT0c5MExOM0xkRjl5VGJjSS1NN2jSAYoBQVVfeXFMT1J2UFFLZ2huendrTThlUnVkTU4zUHFMd3dfMVJyYmxSSVNaanBmbFNELTVGMjZuVGlnWk1sQThWMmlaVUNZTFBNblRGWTBSb1NGeXBacW9hamlGNjFKZnB5V2VmMlVfYjRsQjlZdkZJM2RxUGpHX0MyMXJmUTM0ZGtzWVlEZ2RtcVhn?oc=5" target="_blank">AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
How Did a Heart Drug With So Much Promise Fall So Flat?
The New York Timesgeneral

How Did a Heart Drug With So Much Promise Fall So Flat?

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9kZFY5SVNBZ0VnSGNrM1JyemFaQUdkWjVoR2N0aVVIbDNsRHFtbi1XVURfR0lYdm0wUnp1U2hBTlBiNVpQYUxoRFh1dktXQ012V0Z6VG9vUkZfVHJ5MnZGM1hfT2NzVnJ2dkY4QzNjLW5GWnNtdHhic0t1UlNqdjg?oc=5" target="_blank">How Did a Heart Drug With So Much Promise Fall So Flat?</a>  <font color="#6f6f6f">The New York Times</font>

Read Full StoryMore like this
Novartis twin drug trial setbacks pile pressure on pipeline, CEO
Reutersgeneral

Novartis twin drug trial setbacks pile pressure on pipeline, CEO

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNMFhlWVprMlBUTENuN2xCUEM0dUpweUxxdjdUVmpkNEQydkZqUWVpeFRTYXowZG5vdWxuUEhvc2VabDZpYllTUG9BaHB3cFMyZ1JZSnJhNGY0QnlsX3VyTUFUeTF2RS1Gc19xZ1RtQU1vTW5nMzQ0ZEgwZXZNTXI3REtIdVFQYUdGSW55aHJuVm9iNUY3ZFAxNV9LSnBnYTFGWnF2eXM5ZjkwRVd3OF9YV2VfTlg4YmxVRHU2TjZn?oc=5" target="_blank">Novartis twin drug trial setbacks pile pressure on pipeline, CEO</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Novo drug trial fail deals setback to bid to expand beyond obesity
Reuterstech

Novo drug trial fail deals setback to bid to expand beyond obesity

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPR0hId1RlLVEwR1pIdkEtOVA2QklyZ0l5TE1INUJKR3plRklPLXZFVXNBdkpWSGc1bm92QVF4NWJMR2QxUHlhUUlGdGk1NHN3Q3RpVHdSZ084YkhhRnlMRTVaZFBaWDF2dTJDZkZaOHZVNXdQaXc5bGZDc2d2bTVvNFBNUXEzQjJWcE9hRlRqamtuTE1leUxBdFBMaDhWUE5IR1cyR0hta0VsN2RMWVNlS291ZmRISElfMjNLSVVxdC0?oc=5" target="_blank">Novo drug trial fail deals setback to bid to expand beyond obesity</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
AstraZeneca 'magic' faces rare test after trial failure, share slide
Reuterstech

AstraZeneca 'magic' faces rare test after trial failure, share slide

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPR0g4ZlpxNDdMMDVHcV9Ka1BjMTJRZkFPVkQ0eGxUaXJzSmJQU2NEM2pLX3Y4bERtcTg4M2tjemFvYWtuWlZvdzhRRGlPMThvY2JMU1h3UkR4b3VQUEZaaEFEbkFEb3k0aTN6ajloU3hkLXpYUFVJQ0o5RDVOeE03UUhCSnBmMkJOSC01VUwyOG5yT0NpMmVBRk02NkNRMnhCajlYb0RYb0k2RVI4bmVwNzNXWnhFMkxqYU54SEdCQUZGcnZvV3NFaVRRTS1MR0tIZXk4?oc=5" target="_blank">AstraZeneca 'magic' faces rare test after trial failure, share slide</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Recent Cancer Trial Failures and Setbacks: A Quick Look
Oncology News Centraltech

Recent Cancer Trial Failures and Setbacks: A Quick Look

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQbzBKOGFvdFcwdlJtN1BhVGt5b1VIZGItN0h6NEVlZjRvZkRMMGZsUEJ6X0ljZENVaG5GRUZLaElTbWszVHE1SzJsdk5HczdzMTJtUk5QZEhUOTdKNVZMNXhDN19UZlB5TDczd2VidGlHX2RGRmhPNnl4MjJqUlVrY0xpYW1hTFZyd1RyZWtDZl8?oc=5" target="_blank">Recent Cancer Trial Failures and Setbacks: A Quick Look</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
MedCity Newsscience

QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE52cy05YnVoOUNFaUxmNE1qUlp5cldDbnl0VnVFMlVMQWdETk9PVEt6UXlKcDFlTzdkWlY1X2dOcHRjSnVaUFRVMmRhcG5EYVhiUlE2MHI4YU9uQ1BHN25nX0Yxd25UbGtJZTEzREVPYw?oc=5" target="_blank">QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll</a>  <font color="#6f6f6f">MedCity News</font>

Read Full StoryMore like this
Pharma major Novartis falls 10% after three drug trial setbacks
CNBCgeneral

Pharma major Novartis falls 10% after three drug trial setbacks

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9WRTg5RHNwODJqN0twNlIteDJySzZOWk9CZXU0QzlZQmZram5Ya3QzeUhCTzdOQmJGX2NnenB2VTB0STZpMmJBLVZCYWZRUHB4elFZTER3WXp1b25sSGVxYXBfX09nM1J6VVJUMGlBVFl0MWd2Sm5vaWpGS2RXQdIBgwFBVV95cUxOZFNRTnU3cHFQOExSSHhzRjdmUkpnOGo0N2JFVXFJZWx4NHVGZ3RzcUdrWDBVR3lnRl9tbUlKbnc2aDhpM3V5RDBJSUtiZUtLRU1QakpaQnBLYk9lMXVJakI4Qm1aNUlKampmbm1TeUJJU0lSWlNIY21SVWFZNHlwWlJwcw?oc=5" target="_blank">Pharma major Novartis falls 10% after three drug trial setbacks</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Why Breast Cancer Clinical Trials Stop Early: Poor Accrual Remains the Leading Threat to Study Completion
Oncodailytech

Why Breast Cancer Clinical Trials Stop Early: Poor Accrual Remains the Leading Threat to Study Completion

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAyTUY1NmhZR0VoOEZ6Y0dFVk5Mbml0UWFsWl9OWXVwRkswUVBhZm1uOW1rRVlrcEhnYnY3a18yTkhOQkVfN0xhV0Z4V0dBUW0xV0hqNWtyODBTQjlJa2pLTzM5TmVVbXFTOHdmazRNZmxWcmRCNUJxYm13?oc=5" target="_blank">Why Breast Cancer Clinical Trials Stop Early: Poor Accrual Remains the Leading Threat to Study Completion</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Designed for Performance, Part 1: Recruitment Is a Design Outcome, Not an Operational Failure
Applied Clinical Trialstech

Designed for Performance, Part 1: Recruitment Is a Design Outcome, Not an Operational Failure

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNazF2YUpFcFVtQWVrSzU2cG9YMkxYc0VOVTM5cl9ubkt4T0d2ajBkeHBxTlRVenp2QmxVOUc5d1F5d21FVldiXzZKSzM5RzEydlo3bGRocHgtei1MazdOTGFjLWE0Q05nemJxQXRwZkYycU9DYzIwUkQyc1ZMNUNrWW92VTdfVzZwMUxhNjUzcTZySG1uWXVhV0RDOGpPb2o1cE4yMHNSdHdZX2U3Snc?oc=5" target="_blank">Designed for Performance, Part 1: Recruitment Is a Design Outcome, Not an Operational Failure</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials
The New York Timesgeneral

F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTFBWZFNxaEJ5ZDNlZ0Jmd3J6TVhnUEhZMTE1OGVPZzZvZFVQaTZBZlNSTzJiVG96ai1zTnIwckdnQnk2bEZiLWphZVZ5UmozSzFqaGNlSTlENUY2M1NvM05LRkVybEx5ZGgxbEdqQ05DTlZjQQ?oc=5" target="_blank">F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials</a>  <font color="#6f6f6f">The New York Times</font>

Read Full StoryMore like this
Interventions Are Needed to Prevent Clinical Trial Failure in HNSCC
OncLivetech

Interventions Are Needed to Prevent Clinical Trial Failure in HNSCC

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOSXl1TzlwcFV1RWgtZmVEV2dkRmpuai00c1FRcVZFYnV6R1JQSVFOZ09jd1RaUUFFZDl5eXNpSTZDLTg1UmNiOEZOUmV1VDZjSnY4Nkx5U0lJWndScWRpbmRmNzI3Z2k3UHhLcnBXUXFqVFRfSG0tTjVFaW9OSnhRcmd5Z1FXbGVqT1pHUEdNVjZPYmgyS29zNm03TUw?oc=5" target="_blank">Interventions Are Needed to Prevent Clinical Trial Failure in HNSCC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
Pharmaceutical Executivetech

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQLVBnRFFHTXFEMnZKRTlHQlFicG5NS1RhRGMxMlNvRXVibWNOekJmajBsRUZlVS1KRDVZQW5ELWxFckZXdTJtQWk2ZkpCc212dDE2d0VHQ1VGRHBZbDB5TVhySWFidnYwVUx5a2J6M2VMbWxGMVl2eEF0dWhVaE5KdFhB?oc=5" target="_blank">Ultragenyx Shares Drop Following Failed Phase III Clinical Trial</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
CNBCtech

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQajQtQUd4QTdEZkxVeV9fQkRodGxKM1FKMXJ1ZGxTa056NTdPR09kRHRETVB6ZFVvTHNZQzI0RVZEM2NDN1RmTE1PbjdRYmJrdHFuV2xTS2lOeEVvT3lEcnlIMU9reW8wbXVxXzRkejZmVGp3Snk5d1hhOGJkZ0dETi1yS1ZNQ3BQQ2VjNEY5MnfSAZYBQVVfeXFMTUViakhPaDlVZFVHdXNpNjQ5SDZzNFV2SDB2MmoySlFWOTBUT202QTZMN3pneVdqUjkyUVBhNFJ3T3pLT0MzekJFZnBaSmdSYzcxVGFBWmJmZEFfbDhUSUx2U1d6aDZXOXBzT3VlWWJWUm5FaERJZ1JSMDhFSDNZR0JNS1RteTZndzMybDh2cU1NZWNNV2ZB?oc=5" target="_blank">AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more
STATtech

Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQWjkwMWxUaW5CalN6OHhZZ0lrY1pQaERld2J5Z21KemFQLVVoY25zeHZibS1ESkQzQks1WU5XYzlYeV92MlRWaEtBcUpNdWpaNHJSNVU1ZEktZUlMVFJSMGFIY1FpeG5qSktrVlYzNkMyQTJkeHNlY21Va2lYUTJvM1dsN0paMnFrZ1VrN2N5ZWE5TEJRdHI1ckNBbFIwMXhuU25CUm13?oc=5" target="_blank">Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
"Clinical Trial Failure Is" — Live Google News Trends & Headlines